Abstract: The present invention relates to compositions or vaccines for combating Mycoplasma hyopneumoniae (M hyo), Porcine Circovirus type 2 (PCV2), and Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) infections in animals and for increasing the ability of pigs to gain weight and/or improve death loss, methods of vaccination against the infections, and kits for use with such methods and compositions.

Abstract: NX-019 is a potent, orally administrable small molecule inhibitor of EGFR that shows selective inhibition activity for EGFR having one or more mutations. This present disclosure provides methods of treating EGFR mutant cancer which include orally administering a therapeutically effective amount that is a daily dose of 37.5 mg to 450 mg of NX-019 to a human patient having cancer with at least one mutation in the epidermal growth factor receptor (EGFR) gene. Also provided are methods of treating cancer in a patient having CNS metastasis which includes orally administering a therapeutically effective amount that is a daily dose of 37.5 mg to 450 mg of NX-019 to a human patient having cancer with CNS metastasis and at least one mutation in the epidermal growth factor receptor (EGFR) gene. In some embodiments, the EGFR mutant cancer is NSCLC.

Abstract: Disclosed herein are compounds and compositions having potency in the modulation of Myc family proteins. Such compounds and compositions can be used in the treatment of proliferative diseases, such as cancer, or in the treatment of disease where modulation of Myc family proteins is desired. Also disclosed herein are methods of using said compounds and compositions.

Abstract: Disclosed herein are compounds and compositions having potency in the modulation of Myc family proteins. Such compounds and compositions can be used in the treatment of proliferative diseases, such as cancer, or in the treatment of disease where modulation of Myc family proteins is desired. Also disclosed herein are methods of using said compounds and compositions.

Abstract: A computing system of an organization receives data through multiple channels of communication; a programmatic interface for each of the different channel infrastructures may be called to convert data about a user's contact with the system. Contact records for contain data such as a user ID and a channel identifier. An operational database may receive the converted contact records from the devices or software. A transaction application may perform various tasks resulting in the generation of transaction data. A transaction record containing the transaction data may be generated in a message queue or operational database. The interface for the communication channel may convert the transaction data in a message queue, after the transaction data is detected by a listening application that monitors the message queue and logs new transaction data to the operational database.

Abstract: One embodiment provides a pyranometer, including: a dome; a thermopile-based sensor comprising a receiving surface; a diffusor configured to diffuse radiation external to the pyranometer and passing through the dome, toward the receiving surface of thermopile-based sensor; and at least one optical filter arranged in an optical path of the radiation in front of the receiving surface of the thermopile-based sensor so as to modify the spectral composition of the radiation measured by the thermopile-based sensor. Other aspects are described and claimed.

Abstract: The present invention relates to compositions or vaccines for combating Mycoplasma hyopneumoniae (M hyo), Porcine Circovirus type 2 (PCV2), and Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) infections in animals and for increasing the ability of pigs to gain weight and/or improve death loss, methods of vaccination against the infections, and kits for use with such methods and compositions.

Abstract: Disclosed herein are compounds and compositions having potency in the modulation of Myc family proteins. Such compounds and compositions can be used in the treatment of proliferative diseases, such as cancer, or in the treatment of disease where modulation of Myc family proteins is desired. Also disclosed herein are methods of using said compounds and compositions.

Abstract: Disclosed herein are compounds and compositions having potency in the modulation of Myc family proteins. Such compounds and compositions can be used in the treatment of proliferative diseases, such as cancer, or in the treatment of disease where modulation of Myc family proteins is desired. Also disclosed herein are methods of using said compounds and compositions.

Abstract: Provided herein are methods of treating acute myeloid leukemia (AML) and multiple myeloma (MM) by administering an effective amount of a cell population comprising natural killer cells, wherein the cell population comprising natural killer cells is produced by a three-stage method comprising culturing a population of hematopoietic stem or progenitor cells in media comprising stem cell mobilizing factors, e.g., three-stage methods of producing NK cells in media comprising stem cell mobilizing factors starting with hematopoietic stem or progenitor cells from cells of the placenta, for example, from placental perfusate (e.g., human placental perfusate) or other tissues, for example, umbilical cord blood or peripheral blood. Further provided herein are methods of using the NK cells produced by the three-stage methods provided herein to suppress the proliferation of acute myeloid leukemia cells.

Abstract: A computing system of an organization receives data through multiple channels of communication; a programmatic interface for each of the different channel infrastructures may be called to convert data about a user's contact with the system. Contact records for contain data such as a user ID and a channel identifier. An operational database may receive the converted contact records from the devices or software. A transaction application may perform various tasks resulting in the generation of transaction data. A transaction record containing the transaction data may be generated in a message queue or operational database. The interface for the communication channel may convert the transaction data in a message queue, after the transaction data is detected by a listening application that monitors the message queue and logs new transaction data to the operational database.

Abstract: A method of upgrading refining streams with high polynucleararomatic hydrocarbon (PNA) concentrations can include: hydrocracking a PNA feed in the presence of a catalyst and hydrogen at 380° C. to 430° C., 2500 psig or greater, and 0.1 hr?1 to 5 hr?1 liquid hourly space velocity (LSHV), wherein the weight ratio of PNA feed to hydrogen is 30:1 to 10:1, wherein the PNA feed comprises 25 wt % or less of hydrocarbons having a boiling point of 700° F. (371° C.) or less and having an aromatic content of 50 wt % or greater to form a product comprising 50 wt % or greater of the hydrocarbons having a boiling point of 700° F. (371° C.) or less and having an aromatic content of 20 wt % or less.

Abstract: Provided herein are methods of producing natural killer (NK) cells using a three-stage expansion and differentiation method with media comprising stem cell mobilizing factors. Also provided herein are methods of suppressing tumor cell proliferation using the NK cells and the NK cell populations produced by the three-stage methods described herein, as well as methods of treating individuals having cancer or a viral infection, comprising administering the NK cells and the NK cell populations produced by the three-stage methods described herein to an individual having the cancer or viral infection.

Abstract: The present disclosure provides processes for hydroprocessing hydrocarbon feedstocks comprising a silicon content of about 1 wppm or greater. In at least one embodiment, a process includes introducing, in a reactor or to the reactor, a hydrocarbon feedstock having a silicon content of at least about 1 wppm, based on the total weight of the hydrocarbon feedstock, to a treat gas to produce a hydrocarbon feedstock/treat gas mixture. The process includes introducing the hydrocarbon feedstock/treat gas mixture to a catalyst composition comprising at least one group 6 metal and at least one group 8-10 metal, wherein the molar ratio of group 6 metal to group 8-10 metal is from about 10:1 to about 1:10. The process includes obtaining a liquid product comprising a sulfur content of 5,000 wppm or less. Furthermore, processes of the present disclosure provide hydroprocessing of high Si content feeds using hydrocarbon feeds at high liquid hourly space velocities.

Abstract: The invention relates to the purification of bispecific antibodies carrying a different specificity for each binding site of the immunoglobulin molecule from a mixture of monospecific antibodies. The bispecific antibodies are composed of a single heavy chain and two different light chains, one containing a Kappa constant domain and the other a Lambda constant domain. This invention in particular relates to the isolation of these bispecific antibodies from mixtures that contain monospecific antibodies having two Kappa light chains or portions thereof and monospecific antibodies having two Lambda light chains or portions thereof. The invention also provides the methods of efficiently purifying these bispecific antibodies.

Abstract: A method of upgrading refining streams with high polynucleararomatic hydrocarbon (PNA) concentrations can include: hydrocracking a PNA feed in the presence of a catalyst and hydrogen at 380° C. to 430° C., 2500 psig or greater, and 0.1 hr?1 to 5 hr?1 liquid hourly space velocity (LSHV), wherein the weight ratio of PNA feed to hydrogen is 30:1 to 10:1, wherein the PNA feed comprises 25 wt % or less of hydrocarbons having a boiling point of 700° F. (371° C.) or less and having an aromatic content of 50 wt % or greater to form a product comprising 50 wt % or greater of the hydrocarbons having a boiling point of 700° F. (371° C.) or less and having an aromatic content of 20 wt % or less.

Abstract: A base station for wireless network uses one or more MIMO channels having subchannels, to communicate with multiple user equipments, and allocates the sub channels to the user equipments. Different subchannels of a given one of the channels can be allocated to different user equipments. The ability to allocate sub channels individually rather than only allocating entire channels can enable higher data rates to be achieved. This is particularly useful for improving data rates at cell boundaries or sector boundaries, where the coverage is traditionally weakest. A user equipment can use subchannels from different MIMO channels from different sectors or from different base stations.

Abstract: The invention relates to the purification of bispecific antibodies carrying a different specificity for each binding site of the immunoglobulin molecule from a mixture of monospecific antibodies. The bispecific antibodies are composed of a single heavy chain and two different light chains, one containing a Kappa constant domain and the other a Lambda constant domain. This invention in particular relates to the isolation of these bispecific antibodies from mixtures that contain monospecific antibodies having two Kappa light chains or portions thereof and monospecific antibodies having two Lambda light chains or portions thereof. The invention also provides the methods of efficiently purifying these bispecific antibodies.

Abstract: A computing system of an organization receives data through multiple channels of communication; a programmatic interface for each of the different channel infrastructures may be called to convert data about a member's contact with the system. Contact records for contain data such as a member ID and a channel identifier. An operational database may receive the converted contact records from the devices or software. A transaction application may perform various tasks resulting in the generation of transaction data. A transaction record containing the transaction data may be generated in a message queue or operational database. The interface for the communication channel may convert the transaction data in a message queue, after the transaction data is detected by a listening application that monitors the message queue and logs new transaction data to the operational database.

Abstract: Provided herein are methods of treating acute myeloid leukemia (AML) and multiple myeloma (MM) by administering an effective amount of a cell population comprising natural killer cells, wherein the cell population comprising natural killer cells is produced by a three-stage method comprising culturing a population of hematopoietic stem or progenitor cells in media comprising stem cell mobilizing factors, e.g., three-stage methods of producing NK cells in media comprising stem cell mobilizing factors starting with hematopoietic stem or progenitor cells from cells of the placenta, for example, from placental perfusate (e.g., human placental perfusate) or other tissues, for example, umbilical cord blood or peripheral blood. Further provided herein are methods of using the NK cells produced by the three-stage methods provided herein to suppress the proliferation of acute myeloid leukemia cells.